Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6163| Title: | A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16) | Authors: | Anna Kalff Jake Shortt Flora Yuen John Reynolds Hang Quach Craig Wallington-Gates Patricia Walker Simon Harrison Dunn Rosanne Andrew Spencer |
Issue Date: | 2019 | Publisher: | Wolters Kluwer Health | Source: | HemaSphere, 2019 | Journal Title: | HemaSphere | Abstract: | Background:KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD ® -treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a minimally pre-treated MM population. | DOI: | 10.1097/01.HS9.0000563808.41508.98 | metadata.dc.rights.holder: | Craig Wallington-Gates | Type: | Article |
| Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.